Jun 27, 2022 6:53 am EDT Kiora Pharmaceuticals Receives Clinical Trial Approval for First-in-Human Evaluation of KIO-301 to Restore Vision in Patients with Retinitis Pigmentosa
May 31, 2022 4:30 pm EDT Kiora Pharmaceuticals Receives Nasdaq Notification of Non-Compliance with Listing Rule 5250(c)(1)
Apr 25, 2022 6:45 am EDT Kiora Pharmaceuticals Announces Presentation of KIO-101 Clinical Trial Data at the American Society of Cataract and Refractive Surgery 2022
Mar 21, 2022 6:45 am EDT Kiora Pharmaceuticals to Participate in Maxim Group's 2022 Virtual Growth Conference March 28th - 30th
Mar 18, 2022 6:45 am EDT Kiora Pharmaceuticals Granted Orphan Drug Designation for KIO-301, an Investigational Drug for the Treatment of Retinitis Pigmentosa (RP)
Feb 8, 2022 6:45 am EST Kiora Pharmaceuticals Announces Participation at 2022 BIO CEO & Investor Conference
Feb 1, 2022 6:45 am EST Kiora Pharmaceuticals Appoints Erin Parsons to its Board of Directors; Stephen From to Retire from Board
Jan 5, 2022 7:00 am EST Kiora Pharmaceuticals to Provide 2022 Business Outlook at the H.C. Wainwright Bioconnect Virtual Conference
Dec 15, 2021 7:00 am EST Kiora Pharmaceuticals Appoints David Hollander, MD, MBA, to its Board of Directors